triclinic, P1 (no. 2), a = 4.511(2) Å, b = 11.891(6) Å, c = 14.557(7) Å, α = 109.709(9)°, β = 96.971(9)°, γ = 97.054(9)°, V = 718.4(6) Å 3 , Z = 2, Rgt(F) = 0.0449, wR ref (F 2 ) = 0.1052, T = 293(2) K.
Experimental details
Data reduction was carried out using SAINT+ and SADABS [1] . The structure was determined by the intrinsic phasing routines in the SHELXT program [2] and refined in SHELXL [3] by using Olex 2 [4] . All hydrogen atoms were placed in the calculated positions.
Comment
The compounds containing pyrazolo[1,5-a]pyrimidine scaffold have rich biological activities, especially this kind of compounds exhibited strong biological effects on AMPK, MET and VEGF in the field of anti-cancer drugs [5, 6] . Therefore, the related derivatives are ideal lead compounds for the development of anti-cancer drugs. In our previous works, we synthesized (methyl 2-(4-(3-bromopyrazolo[1,5-a] pyrimidin-6-yl) phenyl)acetate) and hoped to introduce aromatic groups into the position of bromine atom by coupling reaction [7, 8] . But some coupling reactions can not be carried out due to the low reactivity of bromide, so we try to synthesize iodide which exhibits higher reactivity than corresponding bromide to adress this problem. In this work, methyl 2-(4-(3-iodopyrazolo [1,5-a]pyrimidin-6-yl)phenyl)acetate was synthesized by a simple halogenation reaction using N-iodosuccinimide.
The crystallographically independent molecule of the crystal structure is shown in the figure. The NMR and LC-MS results are consistent with the proposed structure. The bond lengths and angles are in the normal ranges. The subsequent experiments showed that iodide has proper reactivities to introduce diverse aryl functional group into title compounds, which is very important to develop novel anticancer drugs.
